

ASX Announcement

15 May 2024

Results of Extraordinary General Meeting

Melbourne, Australia – 15 May 2024: Pancreatic cancer treatment device company **OncoSil Medical Ltd (ASX: OSL)** (“**OncoSil**” or the “**Company**”) advises that all resolutions considered at the Extraordinary General Meeting held today were carried by poll.

In accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, details of the proxies received and votes cast in respect of each resolution are attached.

Christian Dal Cin
CFO & Company Secretary

**OncoSil Medical Ltd
General Meeting
Wednesday, 15 May 2024
Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1. Approval of issue of Placement Options	Ordinary	295,409,965 93.36%	4,310,193 1.36%	16,709,160 5.28%	13,447,660	330,255,414 98.71%	4,310,193 1.29%	13,447,660	Carried	NA
2. Ratification of prior issue of Placement Shares	Ordinary	270,149,101 92.82%	4,236,753 1.46%	16,667,236 5.73%	38,823,888	304,952,626 98.63%	4,236,753 1.37%	38,823,888	Carried	NA
3. Approval of issue of shares and options to Douglas Cubbin (or nominee)	Ordinary	265,666,625 93.70%	5,624,453 1.98%	12,250,902 4.32%	26,681,913	296,053,816 98.14%	5,624,453 1.86%	26,681,913	Carried	NA

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.